BioHarvest Sciences (NASDAQ:BHST) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

BioHarvest Sciences (NASDAQ:BHST) announced its quarterly earnings results on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.04), FiscalAI reports. BioHarvest Sciences had a negative return on equity of 76.03% and a negative net margin of 32.54%.The firm had revenue of $8.84 million during the quarter, compared to the consensus estimate of $9.45 million.

BioHarvest Sciences Stock Performance

Shares of BHST stock traded up $0.02 on Tuesday, reaching $2.12. The stock had a trading volume of 71,347 shares, compared to its average volume of 36,397. The stock has a market cap of $41.65 million, a P/E ratio of -3.55 and a beta of 0.98. BioHarvest Sciences has a 1 year low of $1.82 and a 1 year high of $12.80. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.44 and a current ratio of 2.96. The company has a 50 day simple moving average of $2.77 and a 200 day simple moving average of $3.82.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of BioHarvest Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 18th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Alyeska Investment Group L.P. purchased a new position in BioHarvest Sciences in the fourth quarter worth about $3,929,000. Evercore Wealth Management LLC purchased a new stake in shares of BioHarvest Sciences during the 4th quarter valued at about $724,000. Osaic Holdings Inc. lifted its stake in shares of BioHarvest Sciences by 5,510.4% in the 4th quarter. Osaic Holdings Inc. now owns 35,233 shares of the company’s stock worth $183,000 after purchasing an additional 34,605 shares during the period. XTX Topco Ltd bought a new position in shares of BioHarvest Sciences in the 4th quarter worth approximately $173,000. Finally, Jane Street Group LLC purchased a new position in shares of BioHarvest Sciences in the fourth quarter worth approximately $145,000.

BioHarvest Sciences News Summary

Here are the key news stories impacting BioHarvest Sciences this week:

• Positive Sentiment: BioHarvest secured an exclusive manufacturing and supply agreement with an existing UAE-based fragrance customer for 20 tons of a rare botanical fragrance ingredient over 2027 and 2028. The company estimates the deal could generate approximately $20 million to $30 million in revenue and become the foundation of a profitable CDMO manufacturing business. BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance
• Positive Sentiment: The agreement supports BioHarvest’s strategy of expanding into high-margin, sustainable fragrance manufacturing, with management indicating it will pursue additional opportunities in the rare fragrance market. The contract also provides greater visibility into future production demand. BioHarvest posts higher Q2 revenue, secures manufacturing deal for premium fragrance compound
• Positive Sentiment: Second-quarter revenue rose 3.8% year over year to approximately $8.8 million, while the company said spending was being directed toward manufacturing capacity to support future growth. BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.